• News
  • SAN DIEGO
  • General

La Jolla Pharmaceutical enters agreement with Stanford University

La Jolla Pharmaceutical Co. (Nasdaq: LJPC), a biotechnology company developing therapeutics targeting significant unmet diseases, announced Monday it has signed an option agreement with Stanford University that will add proprietary technology to the company’s programs.

The option agreement with Stanford allows La Jolla Pharmaceutical to test the technology, potentially adding product opportunities to La Jolla Pharmaceutical’s pipeline.

La Jolla Pharmaceutical is currently testing novel oral formulations using the technology in an animal model of non-alcoholic steatohepatitis (NASH). If successful, these product candidates will add to the company’s growing pipeline that includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload and rare diseases.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

La Jolla Pharmaceutical Co.

Company Website

6455 Nancy Ridge Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LJPC
23.87
  -0.82  
- 3.32%
149,217,000
44.99
7.97

Insider Trade Data

Date Insider Shares Type Value
09/28/2015 Chawla, Lakhmir S 485 Purchase $13,461
09/28/2015 Chawla, Lakhmir S 485 Purchase $13,461
09/10/2015 Tang, Kevin C 80,000 Purchase $3,040,000
09/10/2015 Tang, Kevin C 80,000 Purchase $3,040,000
08/21/2015 Tang, Kevin C 170,000 Purchase $4,609,230

La Jolla Pharmaceutical Co. Executive(s):

Deirdre Gillespie

  • Chief Executive Officer, President

George Tidmarsh

  • Chief Executive Officer, President

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)